Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse for TBI-related attention deficits in children
NCT02712996Phase 4Completed
- Sponsor
- Vanderbilt University
- Start
- Feb 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Vanderbilt University. Started Feb 2017; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02712996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712996.